How To Deal With A Dawn Raid By Competition Authorities
Executive Summary
Pharmaceutical firms in Europe are increasingly the target of dawn raids by enforcement authorities in search of evidence of anti-competitive behavior. As John Schmidt and Will Mudge explain, such raids can be highly disruptive and distressing, and companies need to ensure they have robust processes and training in place so that staff can respond appropriately if government agents arrive at their offices unannounced.
You may also be interested in...
How To Be Prepared For A Catastrophic Data Breach
Pharmaceutical companies will be directly affected by the EU’s General Data Protection Regulation because they often hold large amounts of personal health information, such as clinical trial data, and any accidental disclosure of those data will be taken very seriously by the regulatory authorities. Richard Dickinson, Jacqueline Mulryne and Zoe Walkinshaw look at what companies should be doing to limit the impact of a catastrophic data breach on their corporate reputation, the individuals affected, and the validity of the data.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.